Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Lung Cancer
•
Radiation Oncology
What dosimetric and technical precautions/guidelines do you follow when treating a patient with LVAD?
If target is within 5-6 cms of LVAD, what precautions do you take?
Related Questions
How does neoadjuvant chemo-immunotherapy impact your decision on hypofractionation/dose fractionation for locally advanced NSCLC, now getting RT alone?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
How do you assess whether a patient will be a good DIBH candidate for lung or abdomen treatments?
When do you treat heterotopic ossification with radiation pre-operatively?
Does non-urothelial histology impact your approach to chemoradiotherapy for muscle-invasive bladder cancer?
How do you manage a prostate cancer patient with pelvic lymphadenopathy and a single enlarged PSMA PET+ gastrohepatic node?
For a patient who has vaginal cuff recurrence <6 months after adjuvant pelvic radiotherapy to a dose of 45 Gy, how would you approach management?
Is FAST-Forward/ultra-hypofractionation suitable for an early-stage breast patient after a lumpectomy with oncoplastic reduction?
Would you treat a patient for heterotopic ossification prophylaxis if >72 hours after surgery?
What is your approach for LINAC based radiosurgery when dealing with benign perioptic lesions very close to the optics apparatus?